We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

60 hedge funds and large institutions have $123M invested in Spyre Therapeutics in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

13% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 16

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

2% more funds holding

Funds holding: 59 → 60 (+1)

0.08% more ownership

Funds ownership: 2.65% → 2.74% (+0.08%)

12% less capital invested

Capital invested by funds: $140M → $123M (-$17.4M)

Holders
60
Holders Change
+1
Holders Change %
+1.69%
% of All Funds
1.34%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
10
Increased
18
Reduced
16
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.61M
2
BBA
Baker Bros. Advisors
New York
+$2.76M
3
RWM
Ritholtz Wealth Management
New York
+$2.47M
4
BlackRock
BlackRock
New York
+$2.33M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.02M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.54M
2
Jennison Associates
Jennison Associates
New York
-$1.53M
3
Man Group
Man Group
United Kingdom
-$1.49M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$519K
5
SFM
Sphera Funds Management
Israel
-$451K
Name Holding Trade Value Shares
Change 		Change in
Stake
DAM
26
Deltec Asset Management
New York
$287K -$440K -2,073 -58%
TA
27
Teachers Advisors
New York
$222K +$70K +330 +39%
AQR Capital Management
28
AQR Capital Management
Connecticut
$212K – – –
William Blair & Company
29
William Blair & Company
Illinois
$204K – – –
Morgan Stanley
30
Morgan Stanley
New York
$202K -$24.2K -114 -10%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$193K +$7.21K +34 +3%
AG
32
Algert Global
California
$192K +$218K +1,027 New
LF
33
Lee Financial
Texas
$168K – – –
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$162K +$60K +283 +49%
Millennium Management
35
Millennium Management
New York
$156K +$177K +835 New
FSA
36
Franklin Street Advisors
North Carolina
$150K +$170K +800 New
Deutsche Bank
37
Deutsche Bank
Germany
$143K -$153K -721 -48%
TCIM
38
TIAA CREF Investment Management
New York
$141K – – –
Goldman Sachs
39
Goldman Sachs
New York
$132K -$12.5K -59 -8%
Bank of America
40
Bank of America
North Carolina
$128K +$109K +515 +301%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$125K +$142K +668 New
TI
42
Trexquant Investment
Connecticut
$116K +$131K +618 New
SAM
43
Sectoral Asset Management
Quebec, Canada
$97K – – –
AIG
44
American International Group
New York
$81K +$212 +1 +0.2%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$64K – – –
MAM
46
Meeder Asset Management
Ohio
$38K +$13.6K +64 +45%
Canada Pension Plan Investment Board
47
Canada Pension Plan Investment Board
Ontario, Canada
$37K +$42.4K +200 New
SO
48
STRS Ohio
Ohio
$35K – – –
JP Morgan Chase
49
JP Morgan Chase
New York
$32K -$352K -1,660 -91%
Citigroup
50
Citigroup
New York
$32K -$2.33K -11 -6%
1
2
3

SYRE Hedge Fund Activity: Q4 2018 in Review

60 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q4 2018, worth a combined $123M — down 12% from $140M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new SYRE positions and 9 closed out — a net gain of 1 holder — while 18 added to existing stakes and 16 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $4.61M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.54M sold.

  • 60 institutional investors held Spyre Therapeutics (SYRE) as of Q4 2018, up from 59 in Q3 2018.
  • Funds reported $123M of Spyre Therapeutics stock for Q4 2018, down 12% quarter-over-quarter.
  • 10 funds opened new Spyre Therapeutics positions in Q4 2018 and 9 closed out, a net change of +1 holder.
  • The largest Spyre Therapeutics buyer in Q4 2018 was Adage Capital Partners, an estimated $4.61M added.
  • The largest Spyre Therapeutics seller in Q4 2018 was Point72 Asset Management, an estimated $2.54M sold.

Based on aggregated 13F filings for Q4 2018.